Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 36

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
28,256   -   28,256 Reversal of expected credit losses  -   94,912   -   94,912 Others  7,370   99,447   -   106,817 TOTAL OTHER INCOME  52,464   248,417   -   300,881                  OPERATING EXPENSES                Sales and marketing  (56,064)  (1,068,531)  (24,527)  (1,149,122)Research and development  (24,696)  -   -   (24,696)General and administrative  (205,170)  286,724)  (416,772)  (908,666)Fair value loss on investments in equity securities  -   (119,499)  -   (119,499)Provision for expected credit losses   -   (40,124)  -   (40,124)TOTAL OPERATING EXPENSES  (285,930)  (1,514,878)  (441,299)  (2,242,107)                 LOSS FROM OPERATIONS  (231,063)  (557,349)  (441,299)  (1,229,711)                 FINANCE COSTS  (6,637)  (3,101)  (50)  (9,788)                 LOSS BEFORE TAX  (237,700)  (560,450)  (441,349)  (1,239,499)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(237,700) $(560,450) $(441,349) $(1,239,499)

 27Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

   Provision for genomic screening services  Trading of industrial chemicals  Investment holding